Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 41.5
(-5.36%)
SEK 41.5
(-5.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -9.19 Million SEK | 3.55% |
| 2022 | -9.53 Million SEK | -7.46% |
| 2021 | -8.87 Million SEK | -528.63% |
| 2020 | -1.41 Million SEK | 70.62% |
| 2019 | -4.8 Million SEK | -1833.94% |
| 2018 | 277 Thousand SEK | -93.8% |
| 2017 | 4.46 Million SEK | -36.06% |
| 2016 | 6.98 Million SEK | 522.31% |
| 2015 | -1.65 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -2.56 Million SEK | -4.82% |
| 2024 Q2 | -1.41 Million SEK | 136.23% |
| 2023 FY | -9.19 Million SEK | 3.55% |
| 2023 Q3 | 26.97 Million SEK | 0.0% |
| 2023 Q1 | - SEK | 100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | -2.44 Million SEK | -109.08% |
| 2022 FY | -9.53 Million SEK | -7.46% |
| 2022 Q4 | -2.42 Million SEK | -1.13% |
| 2022 Q2 | -2.38 Million SEK | -2.84% |
| 2022 Q3 | -2.39 Million SEK | -0.5% |
| 2022 Q1 | -2.32 Million SEK | -1.09% |
| 2021 Q1 | -1.95 Million SEK | 0.0% |
| 2021 FY | -8.87 Million SEK | -528.63% |
| 2021 Q2 | -2.31 Million SEK | -18.26% |
| 2021 Q3 | -2.3 Million SEK | 0.22% |
| 2021 Q4 | -2.29 Million SEK | 0.48% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | -1.41 Million SEK | 70.62% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 FY | -4.8 Million SEK | -1833.94% |
| 2019 Q4 | - SEK | 0.0% |
| 2018 Q4 | -15.84 Million SEK | -905.44% |
| 2018 Q1 | 9.23 Million SEK | 758.96% |
| 2018 FY | 277 Thousand SEK | -93.8% |
| 2018 Q2 | 9.56 Million SEK | 3.59% |
| 2018 Q3 | 1.96 Million SEK | -79.44% |
| 2017 Q4 | 1.07 Million SEK | -16.06% |
| 2017 Q1 | -3.06 Million SEK | -123.37% |
| 2017 Q2 | 5.17 Million SEK | 268.89% |
| 2017 FY | 4.46 Million SEK | -36.06% |
| 2017 Q3 | 1.28 Million SEK | -75.24% |
| 2016 Q1 | -1.17 Million SEK | 0.0% |
| 2016 FY | 6.98 Million SEK | 522.31% |
| 2016 Q3 | -3.78 Million SEK | -222.75% |
| 2016 Q4 | 13.1 Million SEK | 446.71% |
| 2016 Q2 | -1.17 Million SEK | 0.0% |
| 2015 FY | -1.65 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 94.278% |
| Ziccum AB (publ) | -23.28 Million SEK | 60.517% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 102.655% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 122.002% |
| Mendus AB (publ) | 28.48 Million SEK | 132.274% |
| Genovis AB (publ.) | 54 Million SEK | 117.026% |
| Intervacc AB (publ) | -13.79 Million SEK | 33.348% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 523.491% |
| Active Biotech AB (publ) | -1.67 Million SEK | -448.896% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 192.281% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 134.279% |
| Aptahem AB (publ) | 2.63 Million SEK | 449.496% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -168.752% |
| Kancera AB (publ) | -1.96 Million SEK | -367.888% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 12040.26% |
| Fluicell AB (publ) | 1.73 Million SEK | 628.999% |
| Saniona AB (publ) | 11.78 Million SEK | 178.041% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -79.676% |
| Biovica International AB (publ) | 6.87 Million SEK | 233.692% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 60.512% |
| AcouSort AB (publ) | 8.38 Million SEK | 209.596% |
| Xintela AB (publ) | 78 Thousand SEK | 11887.179% |
| Abliva AB (publ) | -35.66 Million SEK | 74.22% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 93.741% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 427.538% |
| OncoZenge AB (publ) | 3000.00 SEK | 306566.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -376.373% |
| 2cureX AB (publ) | -37.48 Million SEK | 75.474% |
| CombiGene AB (publ) | -21.29 Million SEK | 56.817% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -2073.522% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.814% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.582% |
| Corline Biomedical AB | 28.38 Million SEK | 132.396% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 92.509% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 73.285% |
| I-Tech AB | 27.56 Million SEK | 133.353% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 112.958% |
| Cyxone AB (publ) | 2.61 Million SEK | 452.126% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 370.173% |
| Biosergen AB | -456 Thousand SEK | -1916.228% |
| Cantargia AB (publ) | -3.45 Million SEK | -166.416% |
| NextCell Pharma AB | -43.74 Million SEK | 78.984% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 181.955% |
| Nanologica AB (publ) | -76 Thousand SEK | -11997.368% |
| SynAct Pharma AB | -778 Thousand SEK | -1081.748% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -4663.731% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 28.85% |
| Lipum AB (publ) | 53 Thousand SEK | 17447.17% |
| BioInvent International AB (publ) | 71.46 Million SEK | 112.866% |
| Alzinova AB (publ) | 19.87 Million SEK | 146.261% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 125.329% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 728.426% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -61193.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 654.524% |
| Simris Alg AB (publ) | 2 Million SEK | 558.097% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -156.816% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 125.981% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -776.454% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 393.457% |